This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.
References
Zhu P, Wu Y, Cui D, Shi J, Yu J, Zhao Y, et al. Prevalence of pure red cell aplasia following major ABO-incompatible hematopoietic stem cell transplantation. Front Immunol. 2022;13:829670.
Aung FM, Lichtiger B, Bassett R, Liu P, Alousi A, Bashier Q, et al. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol. 2013;160:798–805.
Longval T, Galimard JE, Leprêtre AC, Suarez F, Amiranoff D, Cazaux M, et al. Treatment for pure red cell aplasia after major ABO-incompatible allogeneic stem cell transplantation: a multicentre study. Br J Haematol. 2021;193:814–26.
Hirokawa M, Fukuda T, Ohashi K, Hidaka M, Ichinohe T, Iwato K, et al. Efficacy and long-term outcome of treatment for pure red cell aplasia after allogeneic stem cell transplantation from major ABO-incompatible donors. Biol Blood Marrow Transplant. 2013;19:1026–32.
Griffith LM, McCoy JP, Bolan CD, Stroncek DF, Pickett AC, Linton GF, et al. Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation. Br J Haematol. 2005;128:668–75.
Chapuy CI, Kaufman RM, Alyea EP, Connors JM. Daratumumab for delayed red-cell engraftment after allogeneic transplantation. N Engl J Med. 2018;379:1846–50.
Bathini S, Holtzman NG, Koka R, Singh Z, Wilding E, Zou Y, et al. Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with Daratumumab. Am J Hematol. 2019. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/ajh.25515.
Salas MQ, Alahmari A, Lipton JH. Successful treatment of refractory red cell aplasia after allogeneic hematopoietic cell transplantation with Daratumumab. Eur J Haematol. 2020;104:145–7.
Rautenberg C, Kaivers J, Germing U, Haas R, Ackerstaff S, Hoffmann T, et al. Daratumumab for treatment of pure red cell aplasia after allogeneic stem cell transplantation. Bone Marrow Transpl. 2020;55:1191–3.
Jeyaraman P, Borah P, Rajput P, Dayal N, Pathak S, Naithani R. Daratumumab for pure red cell aplasia post ABO incompatible allogeneic hematopoietic stem cell transplant for aplastic anemia. Blood Cells Mol Dis. 2021;88:102464.
Yates B, Molloy E, Dulau-Florea A, Braylan R, Hogan L, Hickstein DD, et al. Daratumumab for delayed RBC engraftment following major ABO mismatched haploidentical bone marrow transplantation. Transfusion. 2021;61:1041–6.
Bicsko R, Magyari F, Szasz R, Illes A, Gergely L. Administration of Daratumumab in the case of severe pure red cell aplasia after allogeneic transplantation. Ann Hematol Oncol. 2021;8:1331.
Henig I, Yehudai-Ofir D, Zohar Y, Zuckerman T. Pure red cell aplasia following ABO-mismatched allogeneic hematopoietic stem cell transplantation: resolution with Daratumumab treatment. Acta Haematol. 2021;144:683–7.
Martino R, García-Cadenas I, Esquirol A. Daratumumab may be the most effective treatment for post-engraftment pure red cell aplasia due to persistent anti-donor isohemagglutinins after major ABO-mismatched allogeneic transplantation. Bone Marrow Transpl. 2022;57:282–5.
Li W, Liang L, Liao Q, Li Y, Zhou Y. CD38: an important regulator of T cell function. Biomed Pharmacother. 2022;153:113395.
Ma D, Zhang QY, Rong HM, Zhai K, Tong ZH. Proteomic profiling and functional analysis of B cell-derived exosomes upon Pneumocystis infection. J Immunol Res. 2022;2022:e5187166.
Author information
Authors and Affiliations
Consortia
Contributions
TL and FSdF designed, performed the research and wrote the manuscript. TL, FSdF, AR, AF, EF, TC, RR, AB, NB, GB, MM, FG, FC, MR helped to collect the data. FG, RPdL helped to write the manuscript. All authors read and approved the final manuscript.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Longval, T., Leprêtre, AC., Ravinet, A. et al. Efficacy and safety of Daratumumab for the treatment of ABO-incompatible pure red cell aplasia after allogenic HSCT: report from SFGM-TC. Bone Marrow Transplant (2024). https://doi.org/10.1038/s41409-024-02202-9
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41409-024-02202-9
This article is cited by
-
Daratumumab/erythropoietin/rituximab
Reactions Weekly (2024)